Yüklüyor......

CDK4/6 and IGF1 receptor inhibitors synergize to suppress the growth of p16INK4A-deficient pancreatic cancers

Loss-of-function mutations in p16(INK4A) (CDKN2A) occur in approximately 80% of sporadic pancreatic ductal adenocarcinoma (PDAC), contributing to its early progression. While this loss activates the cell cycle-dependent kinases CDK4/6, which have been considered as drug targets for many years, p16(I...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Heilmann, Andreas M., Perera, Rushika M., Ecker, Veronika, Nicolay, Brandon N., Bardeesy, Nabeel, Benes, Cyril H., Dyson, Nicholas J.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2014
Konular:
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4122288/
https://ncbi.nlm.nih.gov/pubmed/24986516
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-13-2923
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!